Ramipril Shortage UK 2026: SSP Extended, Supply Still Tight

Current Shortage Status: SSP071 Extended

The Serious Shortage Protocol for ramipril 2.5mg tablets — designated SSP071 — remains active and has been extended into 2026. The extension of an SSP is significant: it indicates that supply has not recovered sufficiently to meet demand, and that the NHSBSA (National Health Service Business Services Authority) and DHSC consider an ongoing protocol necessary to manage patient care.

What Is Ramipril and Who Takes It?

Ramipril is an ACE inhibitor — a class of medicine that works by blocking an enzyme (angiotensin-converting enzyme) that causes blood vessels to narrow. By relaxing blood vessels, ramipril reduces blood pressure and makes it easier for the heart to pump blood around the body.

Ramipril is one of the most widely prescribed medicines in the UK. An estimated 5–6 million people in England take an ACE inhibitor, with ramipril being the most commonly used in this class.

Common uses of ramipril

Condition	How ramipril helps
High blood pressure (hypertension)	Relaxes blood vessels, reducing blood pressure
Heart failure	Reduces the load on the heart, improves survival
After heart attack	Protects the heart from further damage
Diabetic nephropathy	Slows kidney damage in people with diabetes
Chronic kidney disease	Provides kidney-protective effect, slows progression
Cardiovascular risk reduction	Reduces risk of heart attack and stroke in high-risk patients

The clinical importance of ramipril means any shortage needs to be managed carefully. For many patients — especially those with heart failure or following a heart attack — stopping or changing their ACE inhibitor without medical guidance could carry real health risks.

What Is a Serious Shortage Protocol?

A Serious Shortage Protocol (SSP) is a legal mechanism introduced in 2019 that gives pharmacists specific powers during medicine shortages. Understanding what an SSP means in practice is important if you are affected by the ramipril shortage.

What an SSP allows pharmacists to do

Under an active SSP, a pharmacist can dispense a specified alternative medicine without requiring you to get a new prescription from your GP. The SSP defines exactly which alternative(s) can be supplied. The pharmacist is responsible for:

• Confirming the alternative is clinically appropriate for you
• Explaining what the alternative is and how to take it
• Documenting the supply on your patient record
• Counselling you on any differences from your usual medicine

What an SSP does NOT mean

• It does not mean your pharmacist can give you any medicine they choose — the SSP specifies the permitted alternatives
• It does not bypass your pharmacist's clinical judgement — they can decline to apply the SSP if it is not appropriate for you
• It does not replace the need to inform your GP — your pharmacist should notify your GP of the switch

How long does an SSP last?

SSPs are issued for a defined period and are extended if supply does not recover. SSP071 for ramipril 2.5mg has already been extended, which reflects the persistent nature of the supply constraint. The NHSBSA reviews active SSPs regularly and will revoke them when supply is restored.

Why Is 2.5mg Specifically Affected?

The 2.5mg strength of ramipril is the starting (titration) dose — the lowest available strength, used when initiating treatment. Here is why it is disproportionately affected:

It's the starting dose for new patients

Clinical guidelines recommend starting ramipril at 1.25mg or 2.5mg for most indications, then titrating up over weeks or months based on blood pressure response and tolerability. The 2.5mg dose is therefore used by two groups: patients who have just started ramipril and are on a low dose, and long-term patients who have settled at 2.5mg as their optimal dose.

Production volumes and margins

Lower-strength formulations often have a smaller market than the 5mg or 10mg versions. With thinner margins across all generic medicines, manufacturers may prioritise higher-volume, higher-revenue strengths when capacity is constrained. The 2.5mg strength is simply more vulnerable in this environment.

Harder to substitute within the same drug

A patient on ramipril 10mg could, in theory, take half a 20mg tablet (if such existed) — though this is not standard practice. A patient on 2.5mg cannot easily split a 5mg tablet to get 2.5mg because splitting unscored tablets is not recommended without specific guidance. This makes the 2.5mg strength functionally irreplaceable without switching to an alternative medicine.

Why Is Ramipril In Shortage?

The structural factors behind the ramipril shortage are similar to those affecting many generic medicines in the UK:

Generic medicine economics

Ramipril is a well-established generic medicine — its patent expired decades ago. This means multiple manufacturers compete on price, driving down margins. When margins are thin, investment in production resilience, safety stock, and manufacturing capacity is limited. A single manufacturing disruption can quickly lead to a nationwide shortage.

Concentrated manufacturing base

Despite the global generic market being large, actual production of ramipril API (active pharmaceutical ingredient) is concentrated in a small number of manufacturing sites, predominantly in India and China. Regulatory actions, quality issues, or logistics problems at any of these sites can cascade into UK supply disruptions.

Demand growth

The UK has seen sustained growth in prescribing of cardiovascular medicines as the population ages and NHS cardiovascular prevention programmes identify and treat more patients. This growing demand, combined with any supply constraint, tips the balance towards shortage.

Post-COVID logistics

Global pharmaceutical supply chains have not fully recovered from the disruptions of 2020-2022. Shipping delays, increased costs, and raw material volatility continue to affect the availability of generic medicines.

Alternative ACE Inhibitors

ACE inhibitors work through the same mechanism and are generally interchangeable for most indications, though individual responses may vary. Under SSP071, your pharmacist may offer one of the following:

ACE inhibitor	Starting dose	Notes
Lisinopril	2.5–5mg once daily	Most commonly prescribed ACE inhibitor. Once daily. Well-established safety profile. Currently widely available.
Enalapril	2.5–5mg twice daily	Twice daily dosing. Long-established. Available in liquid form for patients with swallowing difficulties.
Perindopril	2mg once daily	Once daily. Evidence base includes cardiovascular risk reduction in stable coronary artery disease (EUROPA trial).
Captopril	6.25–12.5mg twice/three times daily	Short-acting, multiple daily doses. Generally used only when liquid is needed or in specific clinical contexts.

Alternative ARBs (Angiotensin Receptor Blockers)

If you are unable to tolerate ACE inhibitors (for example, due to a persistent dry cough, which affects around 10-15% of ACE inhibitor users), an ARB may be considered. ARBs block the same renin-angiotensin system at a different point and have similar blood pressure and organ-protective effects. They are generally better tolerated but historically slightly more expensive.

ARB	Typical starting dose	Notes
Losartan	25–50mg once daily	Most widely used ARB in the UK. Once daily. Well tolerated. Generic, low cost.
Candesartan	4–8mg once daily	Strong evidence base in heart failure. Once daily. Low-cost generic.
Valsartan	40–80mg twice daily	Used in hypertension and heart failure. Note that valsartan has itself had supply issues in the past.
Irbesartan	75–150mg once daily	Once daily. Good evidence in diabetic nephropathy specifically.

What Patients Should Do Right Now

If you take ramipril 2.5mg tablets and are having difficulty obtaining your prescription:

• Visit your pharmacy and explain the supply issue — ask the pharmacist about SSP071
• Your pharmacist can legally supply an alternative ACE inhibitor under SSP071 without a new prescription
• If your pharmacist cannot help, try another local pharmacy — stock levels vary
• Contact your GP if you want to discuss alternatives or if your pharmacist is unable to resolve the issue
• Do not stop taking your blood pressure medicine suddenly — this can cause blood pressure to rise sharply
• Keep a note of your blood pressure readings during any transition — a home blood pressure monitor is useful
• Sign up for MediWatch alerts to be notified when ramipril 2.5mg supply normalises

If you take ramipril for heart failure or post-heart attack

If your ramipril has been prescribed specifically for heart failure or following a myocardial infarction, your situation may be more complex than simple hypertension management. Do not wait for the SSP process alone — contact your GP or cardiology team directly to ensure any transition is appropriately managed. The stakes are higher in these scenarios.

Managing Blood Pressure During Medicine Shortages

A short gap in blood pressure treatment can cause your blood pressure to rise. While a brief interruption is unlikely to cause immediate harm for most people, ongoing periods of uncontrolled hypertension increase the risk of stroke, heart attack, and kidney damage.

Practical steps while your supply is disrupted

• Monitor at home: If you have a home blood pressure monitor (available from most pharmacies), take readings regularly during any transition. Aim for below 130/80 mmHg if possible.
• Lifestyle measures: During any gap in medication, attention to salt intake, alcohol consumption, physical activity, and weight management can help stabilise blood pressure.
• Stay in contact with your GP: If your readings are consistently above 140/90 mmHg without medication, let your GP know.
• Don't panic over one high reading: Blood pressure naturally varies — a single high reading after missing a dose is common. It's patterns over time that matter.

Frequently Asked Questions

Related Medicine Shortages